Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II, open-label, multicenter, randomized clinical trial to evaluate atezolizumab in combination with PEGPH20 in the treatment metastatic pancreatic ductal adenocarcinoma.

Next Previous
X
Search
Trial Profile

A Phase Ib/II, open-label, multicenter, randomized clinical trial to evaluate atezolizumab in combination with PEGPH20 in the treatment metastatic pancreatic ductal adenocarcinoma.

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 May 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Hyaluronidase (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Genentech

    • Most Recent Events

    • 07 May 2020 According to a Roche media release, data from this trial will be presented at the will be presented at the ASCO20 Virtual Scientific Program organised by the American Society of Clinical Oncology (ASCO), which will be held 29-31 May, 2020.
    • 13 Jul 2017 Status changed from planning to recruiting, according to a Halozyme Therapeutics media release.
    • 28 Nov 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top